ライフサイエンスコーパス: cellular cytotoxicity

1 ibodies capable of potent antibody-dependent cellular cytotoxicity.

2 mediated cytotoxicity and antibody-dependent cellular cytotoxicity.

3 ecific antibodies through antibody-dependent cellular cytotoxicity.

4 to those on a healthy diploid cell line for cellular cytotoxicity.

5 virus neutralization, and antibody-dependent cellular cytotoxicity.

6 al antibody, leading to enhanced Fc-mediated cellular cytotoxicity.

7 duction, phagocytosis, and antibody-mediated cellular cytotoxicity.

8 their native counterparts and no significant cellular cytotoxicity.

9 d by viral infection of a host with impaired cellular cytotoxicity.

10 ion rendered tumor cells more susceptible to cellular cytotoxicity.

11 uate eosinophilia through antibody-dependent cellular cytotoxicity.

12 complement activation and antibody-dependent cellular cytotoxicity.

13 sed nuclear translocation of doxorubicin and cellular cytotoxicity.

14 dependent cytotoxicity or antibody-dependent cellular cytotoxicity.

15 tralize SIV isolates, and antibody-dependent cellular cytotoxicity.

16 lls, nor does it diminish antibody-dependent cellular cytotoxicity.

17 ed great in vitro potency and broad spectrum cellular cytotoxicity.

18 o decreases human NK-cell antibody-dependent cellular cytotoxicity.

19 ependent cytotoxicity and antibody-dependent cellular cytotoxicity.

20 an the efficiency of virus neutralization or cellular cytotoxicity.

21 because of their role in antibody-dependent cellular cytotoxicity.

22 rkL is required for efficient NKG2D-mediated cellular cytotoxicity.

23 polymerization inhibition and broad spectrum cellular cytotoxicity.

24 ng center) polarization, and NKG2D-dependent cellular cytotoxicity.

25 s, which in combination reduced Ab-dependent cellular cytotoxicity.

26 utralization, phagocytosis, and Ab-dependent cellular cytotoxicity.

27 proinflammatory chemokines, and significant cellular cytotoxicity.

28 as, interestingly, higher antibody-dependent cellular cytotoxicity.

29 ictates whether a given NK cell will execute cellular cytotoxicity.

30 totoxicity, and increased antibody-dependent cellular cytotoxicity.

31 V-1 isolates and mediated antibody-dependent cellular cytotoxicity.

32 ted effector functions, such as Ab-dependent cellular cytotoxicity.

33 V-1 isolates and mediated antibody-dependent cellular cytotoxicity.

34 treatment also promoted NK and Ab-dependent cellular cytotoxicity activation, which affected leukemi

35 antibodies with enhanced antibody-dependent cellular cytotoxicity activities.

36 nd thereby decreasing the antibody-dependent cellular cytotoxicity activities.

37 They showed greater Ab-dependent cellular cytotoxicity activity against rituximab-opsoniz

38 bs to V2 and increased both the Ab-dependent cellular cytotoxicity activity and the breadth of neutra

39 amma-receptor binding and antibody-dependent cellular cytotoxicity activity was observed upon decorat

40 amma receptor binding and antibody-dependent cellular cytotoxicity activity, abolished all in vivo ef

41 m binding titer, stronger antibody-dependent cellular cytotoxicity activity, and peak prechallenge an

42 eactive oxygen species or antibody-dependent cellular cytotoxicity activity, but led to up to 47% pha

43 may cooperatively elicit antibody-dependent cellular cytotoxicity activity.

44 ference in serum in vitro antibody-dependent cellular cytotoxicity activity.

45 Engagement of Ab-dependent cellular cytotoxicity (ADCC) Abs by NK cells leads to ki

46 ding and neutralizing and antibody-dependent cellular cytotoxicity (ADCC) activity after immunization

47 8 T cells mediated HIV-specific Ab-dependent cellular cytotoxicity (ADCC) activity at levels comparab

48 hose capable of mediating antibody-dependent cellular cytotoxicity (ADCC) activity have been postulat

49 ing MAbs exhibited strong antibody-dependent cellular cytotoxicity (ADCC) activity in a reporter assa

50 of antibodies with potent antibody-dependent cellular cytotoxicity (ADCC) activity in the Thai RV144

51 ependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) activity of the mAbs tested

52 variant with compromised antibody-dependent cellular cytotoxicity (ADCC) activity strongly inhibited

53 and subsequently modulate antibody-dependent cellular cytotoxicity (ADCC) activity.

54 d FcgammaR engagement and antibody-dependent cellular cytotoxicity (ADCC) activity.

55 region of gp120 with high antibody-dependent cellular cytotoxicity (ADCC) activity.

56 orrelated with measurable antibody-dependent cellular cytotoxicity (ADCC) activity.

57 ection may correlate with antibody-dependent cellular cytotoxicity (ADCC) activity.

58 iral particles, to direct antibody-dependent cellular cytotoxicity (ADCC) against actively infected c

59 Antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against avian influenza vir

60 e antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against heterologous influe

61 C/AIDSVax vaccine induced antibody-dependent cellular cytotoxicity (ADCC) against the Env V2 and cons

62 killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cells.

63 e potent than hIgG3 in inducing Ab-dependent cellular cytotoxicity (ADCC) and Ab-dependent cellular p

64 body activities mediating antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell

65 V infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phag

66 Antibody-dependent cellular cytotoxicity (ADCC) and complement fixation bot

67 une effector mechanisms such as Ab-dependent cellular cytotoxicity (ADCC) and complement-dependent cy

68 ector activities, such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, are media

69 ressed cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and their presence correlat

70 HIV-1-specific antibody-dependent cellular cytotoxicity (ADCC) antibodies within HIV-1-pos

71 the i.m. route had lower antibody-dependent cellular cytotoxicity (ADCC) antibody activity, whereas

72 To investigate antibody-dependent cellular cytotoxicity (ADCC) as a contributor to Fcgamma

73 th ACE2 but could involve antibody-dependent cellular cytotoxicity (ADCC) as IgG1 ab1 had ADCC activi

74 An antibody-dependent cellular cytotoxicity (ADCC) assay was used to determine

75 ll activation assays, and antibody-dependent cellular cytotoxicity (ADCC) assays.

76 (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by aggregating FcgammaRIIIA

77 ave been shown to improve antibody-dependent cellular cytotoxicity (ADCC) by allowing more effective

78 Antibody-dependent cellular cytotoxicity (ADCC) by immune effector cells ha

79 ffector functions such as antibody-dependent cellular cytotoxicity (ADCC) contributed to the immunity

80 rowing evidence indicates antibody-dependent cellular cytotoxicity (ADCC) contributes to the clinical

81 nalysis, and had enhanced antibody-dependent cellular cytotoxicity (ADCC) effector function relative

82 dies capable of mediating antibody-dependent cellular cytotoxicity (ADCC) effector functions.

83 zing epitopes targeted by antibody-dependent cellular cytotoxicity (ADCC) effector responses.

84 ime point correlated with antibody-dependent cellular cytotoxicity (ADCC) function at the peak immuni

85 ) Env and able to mediate antibody-dependent cellular cytotoxicity (ADCC) have been shown to be prese

86 s a role for HIV-specific antibody-dependent cellular cytotoxicity (ADCC) in controlling viral infect

87 ecific and cross-reactive antibody-dependent cellular cytotoxicity (ADCC) in HIV-1 and HIV-2 monoinfe

88 role for NK cell-dependent antibody-mediated cellular cytotoxicity (ADCC) in vaccine-induced protecti

89 aRIII binding and improve antibody-dependent cellular cytotoxicity (ADCC) in vitro resulted in arming

90 bodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversely correlate with in

91 Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism

92 Ab-dependent cellular cytotoxicity (ADCC) is believed to be a major a

93 Antibody-dependent cellular cytotoxicity (ADCC) is mediated through the eng

94 Ab-dependent cellular cytotoxicity (ADCC) is one of the most importan

95 Antibody (Ab)-dependent cellular cytotoxicity (ADCC) is thought to potentially p

96 IFN-gamma production and antibody-dependent cellular cytotoxicity (ADCC) is unclear, as are the sign

97 ability of NK cells to mediate Ab-dependent cellular cytotoxicity (ADCC) largely contributes to the

98 Antibody-dependent cellular cytotoxicity (ADCC) may be an important compone

99 Therefore, antibody-dependent cellular cytotoxicity (ADCC) may play a role in cross-pr

100 ibodies (Abs) involved in antibody-dependent cellular cytotoxicity (ADCC) may provide some protection

101 was mediated through the antibody-dependent cellular cytotoxicity (ADCC) mechanism, as anti-CTLA4 wi

102 Ab-dependent cellular cytotoxicity (ADCC) mediated by NK cells is reg

103 ller (NK) cells to induce antibody-dependent cellular cytotoxicity (ADCC) of alphavbeta3-expressing t

104 , CD54 up-regulation, and antibody-dependent cellular cytotoxicity (ADCC) on NK cells from subjects w

105 f HIV-1-infected cells by antibody-dependent cellular cytotoxicity (ADCC) requires the presence of en

106 for the elicitation of a strong Ab-dependent cellular cytotoxicity (ADCC) response for all animals, a

107 sis of HIV-1 virions, and antibody-dependent cellular cytotoxicity (ADCC) responses against gp120-coa

108 Ab-dependent cellular cytotoxicity (ADCC) responses are of growing in

109 well as neutralizing and antibody-dependent cellular cytotoxicity (ADCC) responses in plasma and mil

110 rrelation of HIV-specific antibody-dependent cellular cytotoxicity (ADCC) responses with protection f

111 utralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) responses.

112 of potentially protective antibody-dependent cellular cytotoxicity (ADCC) responses.

113 XmAb5592 increased antibody-dependent cellular cytotoxicity (ADCC) several fold relative to th

114 nt cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the antibody Fc reg

115 rum antienvelope avidity, antibody-dependent cellular cytotoxicity (ADCC) titers, and percent antibod

116 ing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to eliminate infected cells

117 MPORTANCE Mobilization of antibody-dependent cellular cytotoxicity (ADCC) to eliminate reactivated la

118 y infected cells mobilize antibody-dependent cellular cytotoxicity (ADCC) to eliminate the HIV-1-infe

119 ch interest in the potential of Ab-dependent cellular cytotoxicity (ADCC) to slow disease progression

120 rts proposed a role for NK cell Ab-dependent cellular cytotoxicity (ADCC) triggered via FcgammaR-IIIA

121 n the secondary analysis, antibody-dependent cellular cytotoxicity (ADCC) was another inverse correla

122 Antibody-dependent cellular cytotoxicity (ADCC) was measured by a biolumine

123 Previously, Ab-dependent cellular cytotoxicity (ADCC) was significantly correlate

124 ctor functions, including antibody-dependent cellular cytotoxicity (ADCC) which is mediated in part t

125 hat modulate HIV-specific antibody-dependent cellular cytotoxicity (ADCC) will help in understanding

126 tibody-opsonized cells by antibody-dependent cellular cytotoxicity (ADCC), a reaction generally consi

127 ll line-based assays, including Ab-dependent cellular cytotoxicity (ADCC), Ab-dependent cell-mediated

128 plement-dependent cytotoxicity, Ab-dependent cellular cytotoxicity (ADCC), Ab-dependent cellular phag

129 t-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and apoptotic mechanisms o

130 c antibodies, with higher antibody-dependent cellular cytotoxicity (ADCC), and better neutralizing an

131 gp120 and V1V2 responses, antibody-dependent cellular cytotoxicity (ADCC), and low-titer tier 1B and

132 The MAbs mediated antibody-dependent cellular cytotoxicity (ADCC), and mice that received the

133 nding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and modest antibody-depend

134 killer (NK)-cell-mediated antibody-dependent cellular cytotoxicity (ADCC), but little is known about

135 antitumor effects include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cell

136 ctive effects by means of antibody-dependent cellular cytotoxicity (ADCC), in which virus-specific an

137 ng tier 1 neutralization, antibody-dependent cellular cytotoxicity (ADCC), infected cell binding, and

138 atory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being investi

139 also a potent mediator of antibody-dependent cellular cytotoxicity (ADCC), lysing B-CLL cells more ef

140 frequently mediate potent antibody-dependent cellular cytotoxicity (ADCC), making them an important v

141 XmAb5574 mediates potent antibody-dependent cellular cytotoxicity (ADCC), modest direct cytotoxicity

142 ivity, antibodies mediate antibody-dependent cellular cytotoxicity (ADCC), the killing of an antibody

143 nsitize infected cells to antibody-dependent cellular cytotoxicity (ADCC), we treated cells with the

144 n significantly decreases antibody-dependent cellular cytotoxicity (ADCC), whereas terminal alpha2,6-

145 One such mechanism is antibody-dependent cellular cytotoxicity (ADCC), whereby host antibodies bi

146 tion, and protection from antibody-dependent cellular cytotoxicity (ADCC), which is often mediated by

147 to drastic enhancement of antibody-dependent cellular cytotoxicity (ADCC), while terminal alpha2,6-si

148 influenza virus-specific antibody-dependent cellular cytotoxicity (ADCC)-activating antibodies are r

149 al killer (NK) cells, via antibody-dependent cellular cytotoxicity (ADCC)-like mechanism, increase IF

150 is the primary target of antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies presen

151 (Env) recognized by antibody (Ab)-dependent cellular cytotoxicity (ADCC)-mediating antibodies.

152 neage induces HA-specific antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies.

153 lls resulting in crippled antibody-dependent cellular cytotoxicity (ADCC).

154 cytotoxicity but enhanced antibody-dependent cellular cytotoxicity (ADCC).

155 mation are susceptible to antibody-dependent cellular cytotoxicity (ADCC).

156 oengineered for augmented antibody-dependent cellular cytotoxicity (ADCC).

157 ntibodies able to mediate antibody-dependent cellular cytotoxicity (ADCC).

158 ated from latency through antibody-dependent cellular cytotoxicity (ADCC).

159 o destroy Ab-coated targets via Ab-dependent cellular cytotoxicity (ADCC).

160 xpressing cancer cells by antibody-dependent cellular cytotoxicity (ADCC).

161 heir impact on NK cell-mediated Ab-dependent cellular cytotoxicity (ADCC).

162 t CD4i antibodies mediate antibody-dependent cellular cytotoxicity (ADCC).

163 tion and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

164 ing regulatory T cells by antibody-dependent cellular cytotoxicity (ADCC).

165 endent processes, such as antibody-dependent cellular cytotoxicity (ADCC).

166 for its role in mediating antibody-dependent cellular cytotoxicity (ADCC).

167 ral mechanisms, including antibody-dependent cellular cytotoxicity (ADCC).

168 ability of mAbs to induce antibody dependent cellular cytotoxicity (ADCC).

169 s by antibodies mediating antibody-dependent cellular cytotoxicity (ADCC).

170 et cells through the process of Ab-dependent cellular cytotoxicity (ADCC).

171 g and rituximab-mediated, antibody-dependent cellular cytotoxicity (ADCC).

172 c receptor (FcR)-mediated antibody-dependent cellular cytotoxicity (ADCC).

173 utralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC).

174 nsitize infected cells to antibody-dependent cellular cytotoxicity (ADCC).

175 lity of infected cells to antibody-dependent cellular cytotoxicity (ADCC).

176 affects the efficiency of antibody-dependent cellular cytotoxicity (ADCC).

177 to its ability to mediate antibody-dependent cellular cytotoxicity (ADCC).

178 g Fc receptors to mediate antibody-dependent cellular cytotoxicity (ADCC).

179 lity of infected cells to antibody-dependent cellular cytotoxicity (ADCC).

180 tion and NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

181 ent cytotoxicity (CDC) or antibody-dependent cellular-cytotoxicity (ADCC), so as to reduce reliance o

182 zed by increased in vitro antibody-dependent cellular cytotoxicity [ADCC] activity) than the wild-typ

183 atural killer (NK) cells (antibody-dependent cellular cytotoxicity [ADCC]) or complement (complement-

184 nnate immune responses (termed "Ab-dependent cellular cytotoxicity [ADCC]-mediating Abs"), may assist

185 ce of a cross-linker, and antibody-dependent cellular cytotoxicity against B-cell leukemia/lymphoma c

186 l direct cytotoxicity and antibody-dependent cellular cytotoxicity against hematopoietic and nonhemat

187 residues mediated higher antibody-dependent cellular cytotoxicity against human tumor cells.

188 ed antibodies conferred complement-dependent cellular cytotoxicity against MCF-7 and OVCAR-5 cells.

189 Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+HLA-A2+ leukemia cel

190 with concurrent enhanced antibody-dependent cellular cytotoxicity against rituximab-coated CLL cells

191 delta T cells can perform antibody-dependent cellular cytotoxicity against stromal cells coated with

192 cific antibodies mediated antibody-dependent cellular cytotoxicity against tumor cells from human col

193 a are capable of inducing antibody-dependent cellular cytotoxicity, an activity not observed for (CHO

194 mediate effector functions like Ab-dependent cellular cytotoxicity and Ab-dependent cellular phagocyt

195 capable of both achieving antibody-dependent cellular cytotoxicity and blocking of IL-1 signaling as

196 This leads to substantial levels of cellular cytotoxicity and breakdown of tight junctions b

197 antibodies display robust antibody-dependent cellular cytotoxicity and CD4-dependent virion capture a

198 The antibody-dependent cellular cytotoxicity and complement-dependent cytotoxic

199 cted cells by Fc-mediated antibody-dependent cellular cytotoxicity and complement-dependent cytotoxic

200 functions to F(ab')(2) in both Ab-dependent cellular cytotoxicity and complement-dependent cytotoxic

201 t cell killing to promote antibody-dependent cellular cytotoxicity and complement-dependent cytotoxic

202 L-15 genes was able to increase Ab-dependent cellular cytotoxicity and complement-dependent lysis of

203 responses were driven by antibody-dependent cellular cytotoxicity and complement-directed cytotoxici

204 diated both AQP4-directed antibody-dependent cellular cytotoxicity and complement-mediated lysis.

205 have lower and slower replication, and lower cellular cytotoxicity and cytokine and/or chemokine prod

206 -type lectin-like receptor (CTLR) triggering cellular cytotoxicity and cytokine secretion upon high-a

207 antibody had no impact on antibody-dependent cellular cytotoxicity and did not change the affinity of

208 en fatal disorder characterized by defective cellular cytotoxicity and hyperinflammation, and the onl

209 7H6-specific BiTEs direct T cells to mediate cellular cytotoxicity and IFN-gamma secretion upon cocul

210 Cardiac glycoside-induced cellular cytotoxicity and IL-1beta signaling are likewis

211 et for cetuximab-mediated antibody-dependent cellular cytotoxicity and in vivo elimination.

212 s and have disadvantages of variable uptake, cellular cytotoxicity and loss of nanoparticles on cell

213 lity to cetuximab-induced antibody-dependent cellular cytotoxicity and occurred independently of KRAS

214 ffector functions such as antibody-dependent cellular cytotoxicity and phagocytosis.

215 ls were resistant to both antibody-dependent cellular cytotoxicity and signaling-induced cell death.

216 In contrast, antibody-dependent cellular cytotoxicity and T cell activity did not correl

217 cR (FcgammaRIIIa) that mediates Ab-dependent cellular cytotoxicity and the production of immune modul

218 SIV-specific Ab, which mediated Ab-dependent cellular cytotoxicity and was correlated with mucosal NK

219 gp140-specific IgG, ADCC (antibody-dependent cellular cytotoxicity) and some neutralisation activity,

220 plement-dependent cytotoxicity, Ab-dependent cellular cytotoxicity, and Ab-dependent cellular phagocy

221 pendent FcgammaR-mediated antibody-dependent cellular cytotoxicity, and by direct complement-mediated

222 mab to mediate apoptosis, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxi

223 drogenase (LDH) concentration as a marker of cellular cytotoxicity, and cytokine and/or chemokine sec

224 s (antibody dependent cellular phagocytosis, cellular cytotoxicity, and cytokine release).

225 unctions, such as phagocytosis, Ab-dependent cellular cytotoxicity, and cytokine release.

226 PD-specific antibody-dependent phagocytosis, cellular cytotoxicity, and natural killer cell activatio

227 ets through direct lysis, antibody-dependent cellular cytotoxicity, and production of chemokines and

228 responses such as phagocytosis, Ab-dependent cellular cytotoxicity, and respiratory burst.

229 ys, such as phagocytosis, antibody-dependent cellular cytotoxicity, and the recruitment and activatio

230 ization, complement activation, Ab-dependent cellular cytotoxicity, and toxin/viral neutralization.

231 ding apoptosis induction, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phago

232 t-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phago

233 ignaling mechanisms governing NKG2D-mediated cellular cytotoxicity are unknown.

234 Candidates were characterized in cellular cytotoxicity assays with Chinese hamster ovary

235 dent cellular phagocytosis, and Ab-dependent cellular cytotoxicity assays.

236 Fc domain that eliminates antibody-dependent cellular cytotoxicity at clinically relevant doses to pr

237 enhanced NK cell activation and Ab-dependent cellular cytotoxicity at high Ab concentrations.

238 in the treatment of malignant glioma, causes cellular cytotoxicity by forming O(6)-methylguanine addu

239 sical complement pathway, antibody-dependent cellular cytotoxicity by innate immune cell subsets also

240 resulting from mutation in genes involved in cellular cytotoxicity can be crucial.

241 exploratory immunoassays (antibody-dependent cellular cytotoxicity, CD4+ T-cell cytokine production,

242 ssay, but demonstrated significantly reduced cellular cytotoxicity compared to epothilone B.

243 ependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with rituximab.

244 The 20-2b shows enhanced antibody-dependent cellular cytotoxicity compared with veltuzumab but lacks

245 ector functions including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity

246 diated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced pro

247 rted to display increased antibody-dependent cellular cytotoxicity, demonstrates that glycan engineer

248 viously, we demonstrated that NKp65-mediated cellular cytotoxicity depends on tyrosine 7, located in

249 or mechanism of action is antibody-dependent cellular cytotoxicity (eg, trastuzumab in breast cancer

250 ngineered Fc variants for antibody-dependent cellular cytotoxicity enhancement could be embedded in m

251 ment-dependent cytotoxicity and Ab-dependent cellular cytotoxicity favored a membrane-proximal epitop

252 The in vivo half-life, antibody-dependent cellular cytotoxicity function, and binding ability to F

253 on and mediates effective antibody-dependent cellular cytotoxicity in a variety of tumor cells.

254 ese include activation of antibody-dependent cellular cytotoxicity, inhibition of extracellular domai

255 killer (NK) cell-mediated antibody-dependent cellular cytotoxicity involving FcgammaRIIIa (CD16) like

256 Cellular cytotoxicity is essential for the elimination o

257 Nevertheless, in CLL, Ab-dependent cellular cytotoxicity is relatively impaired by the low

258 Cellular cytotoxicity is the hallmark of NK cells mediat

259 likely be ascribed to the antibody-dependent cellular cytotoxicity machinery because IL-27 successful

260 and eliminates them through an Ab-dependent cellular cytotoxicity mechanism in vitro.

261 K cells are largely involved in Ab-dependent cellular cytotoxicity mediated by therapeutic mAbs, such

262 l killer cells to enhance antibody-dependent cellular cytotoxicity, mediates complement-dependent cyt

263 inding, neutralizing, and antibody-dependent cellular cytotoxicity-mediating antibodies against the p

264 ved from broadly binding, antibody-dependent cellular cytotoxicity-mediating antibodies known to bind

265 owed Galcer blocking, the antibody-dependent cellular cytotoxicity-mediating CH38 IgG and its natural

266 s the potential role that antibody-dependent cellular cytotoxicity might play in antilatency cure app

267 The 3.2G1 TCRm-mediated CDC and Ab-dependent cellular cytotoxicity of a human breast carcinoma line i

268 D200-G1 Abs efficiently mediate Ab-dependent cellular cytotoxicity of activated T cells, critical cel

269 immuno-Doxil(R) preparation showed increased cellular cytotoxicity of B16-F10, HeLa and MCF-7 cells w

270 ependent cytotoxicity and antibody-dependent cellular cytotoxicity of CD20-positive human B cells.

271 owth and induces in vitro antibody-dependent cellular cytotoxicity of human neuroblastoma-derived cel

272 f RANKL with induction of antibody-dependent cellular cytotoxicity of natural killer (NK) cells again

273 of S. aureus by neutrophils and Ab-dependent cellular cytotoxicity of tumor cells by both neutrophils

274 tion through mechanisms that did not involve cellular cytotoxicity or apoptosis.

275 of nitric oxide (NO) as a potent mediator of cellular cytotoxicity or signaling.

276 e of antibodies to induce antibody-dependent cellular cytotoxicity or to block iKIRs, or by transduct

277 ct cell death, NK cell-mediated Ab-dependent cellular cytotoxicity, or complement-dependent cytotoxic

278 Ab-dependent cellular cytotoxicity, phagocytosis, and Ag presentation

279 nt effector functions including Ab-dependent cellular cytotoxicity, phagocytosis, and complement fixa

280 ty (virus neutralization, antibody-dependent cellular cytotoxicity, phagocytosis, and virion capture)

281 e increased C1C2-specific antibody-dependent cellular cytotoxicity potency and breadth.

282 through the induction of antibody-dependent cellular cytotoxicity, promotion of antibody-targeted cr

283 a manner associated with antibody-dependent cellular cytotoxicity rather than EGFR pathway inhibitio

284 odies, and high levels of antibody-dependent cellular cytotoxicity responses and HIV-1-neutralizing a

285 Moreover, Ab-dependent cellular cytotoxicity responses inversely correlated wit

286 aptive NK cells dominated antibody-dependent cellular cytotoxicity responses, and their frequency wit

287 binding during phagocytosis and Ab-dependent cellular cytotoxicity, resulting in a phenotype similar

288 Rituximab-mediated cellular cytotoxicity (RMCC) was assessed by lactate deh

289 rotection correlated with antibody-dependent cellular cytotoxicity specific for CD4-induced epitopes,

290 pression, which may be important to regulate cellular cytotoxicity that could otherwise lead to cell

291 They can mediate antibody-dependent cellular cytotoxicity to eradicate tumor cells via recru

292 All the peptide Abs showed Ab-dependent cellular cytotoxicity to varying degrees with the 266-29

293 lls, the key mediators of antibody-dependent cellular cytotoxicity, to human AMR in allotransplantati

294 mor models by stimulating antibody-dependent cellular cytotoxicity toward tumor vessels.

295 isorganization, caveolin-1 inactivation, and cellular cytotoxicity were inhibited when target cells w

296 mokine/cytokine production, and Ab-dependent cellular cytotoxicity were similar between inhibitor-tre

297 Thirty kinases showed significant cellular cytotoxicity when depleted, with loss of the ce

298 ectors of complement- and antibody-dependent cellular cytotoxicity, which are critical mediators of A

299 ependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be

300 might sometimes have mutations that affected cellular cytotoxicity without affecting pigmentation.